Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Dr. Google: Trends in Online Interest in Prostate Cancer Screening, Diagnosis and Treatment.

Rezaee ME, Goddard B, Sverrisson EF, Seigne JD, Dagrosa LM.

BJU Int. 2019 Jun 17. doi: 10.1111/bju.14846. [Epub ahead of print]

PMID:
31206954
2.

Overuse of Cystoscopic Surveillance among Patients with Low-Risk Non-Muscle-Invasive Bladder Cancer - A National Study of Patient, Provider, and Facility Factors.

Han DS, Lynch KE, Chang JW, Sirovich B, Robertson DJ, Swanton AR, Seigne JD, Goodney PP, Schroeck FR.

Urology. 2019 May 27. pii: S0090-4295(19)30448-0. doi: 10.1016/j.urology.2019.04.036. [Epub ahead of print]

PMID:
31145947
3.

The impact of frequent cystoscopy on surgical care and cancer outcomes among patients with low-risk, non-muscle-invasive bladder cancer.

Schroeck FR, Lynch KE, Li Z, MacKenzie TA, Han DS, Seigne JD, Robertson DJ, Sirovich B, Goodney PP.

Cancer. 2019 May 23. doi: 10.1002/cncr.32185. [Epub ahead of print]

PMID:
31120559
4.

MicroRNA Dysregulation and Non-Muscle-Invasive Bladder Cancer Prognosis.

Andrew AS, Karagas MR, Schroeck FR, Marsit CJ, Schned AR, Pettus JR, Armstrong DA, Seigne JD.

Cancer Epidemiol Biomarkers Prev. 2019 Apr;28(4):782-788. doi: 10.1158/1055-9965.EPI-18-0884. Epub 2019 Jan 30.

PMID:
30700445
5.

Noninvasive diagnostic imaging using machine-learning analysis of nanoresolution images of cell surfaces: Detection of bladder cancer.

Sokolov I, Dokukin ME, Kalaparthi V, Miljkovic M, Wang A, Seigne JD, Grivas P, Demidenko E.

Proc Natl Acad Sci U S A. 2018 Dec 18;115(51):12920-12925. doi: 10.1073/pnas.1816459115. Epub 2018 Dec 3.

6.

Extent of Risk-Aligned Surveillance for Cancer Recurrence Among Patients With Early-Stage Bladder Cancer.

Schroeck FR, Lynch KE, Chang JW, MacKenzie TA, Seigne JD, Robertson DJ, Goodney PP, Sirovich B.

JAMA Netw Open. 2018 Sep;1(5). pii: e183442. doi: 10.1001/jamanetworkopen.2018.3442. Epub 2018 Sep 28.

7.

Geographic Variation in Cystoscopy Rates for Suspected Bladder Cancer between Female and Male Medicare Beneficiaries.

Han DS, Zhou W, Seigne JD, Lynch KE, Schroeck FR.

Urology. 2018 Dec;122:83-88. doi: 10.1016/j.urology.2018.08.011. Epub 2018 Aug 20.

PMID:
30138684
8.

Editorial Comment.

Seigne JD.

J Urol. 2018 Nov;200(5):1004. doi: 10.1016/j.juro.2018.06.073. Epub 2018 Jul 19. No abstract available.

PMID:
30030974
9.

Acquired Hemophilia presenting as Gross Hematuria following Kidney Stone - A Case Report and Review of the Literature.

Schmidt-Bowman M, Reinstatler L, Raffin EP, Yared JE, Seigne JD, Sverrisson EF.

Int Braz J Urol. 2018 Mar-Apr;44(2):390-392. doi: 10.1590/S1677-5538.IBJU.2017.0172. Review.

10.

Development of a Natural Language Processing Engine to Generate Bladder Cancer Pathology Data for Health Services Research.

Schroeck FR, Patterson OV, Alba PR, Pattison EA, Seigne JD, DuVall SL, Robertson DJ, Sirovich B, Goodney PP.

Urology. 2017 Dec;110:84-91. doi: 10.1016/j.urology.2017.07.056. Epub 2017 Sep 12.

11.

Assembling and validating data from multiple sources to study care for Veterans with bladder cancer.

Schroeck FR, Sirovich B, Seigne JD, Robertson DJ, Goodney PP.

BMC Urol. 2017 Sep 6;17(1):78. doi: 10.1186/s12894-017-0271-x.

12.

The Burden of Cystoscopic Bladder Cancer Surveillance: Anxiety, Discomfort, and Patient Preferences for Decision Making.

Koo K, Zubkoff L, Sirovich BE, Goodney PP, Robertson DJ, Seigne JD, Schroeck FR.

Urology. 2017 Oct;108:122-128. doi: 10.1016/j.urology.2017.07.016. Epub 2017 Jul 21.

13.

Secular Trends in Prostate Biopsy Criteria and Outcomes: The Dartmouth Experience.

Reinstatler L, Rissman C, Seigne JD, Hyams ES.

Urology. 2017 Sep;107:178-183. doi: 10.1016/j.urology.2017.04.053. Epub 2017 Jul 10.

PMID:
28595934
14.

Qualitative insights into how men with low-risk prostate cancer choosing active surveillance negotiate stress and uncertainty.

Mader EM, Li HH, Lyons KD, Morley CP, Formica MK, Perrapato SD, Irwin BH, Seigne JD, Hyams ES, Mosher T, Hegel MT, Stewart TM.

BMC Urol. 2017 May 8;17(1):35. doi: 10.1186/s12894-017-0225-3.

15.

Impact of a decision aid on newly diagnosed prostate cancer patients' understanding of the rationale for active surveillance.

Formica MK, Wason S, Seigne JD, Stewart TM.

Patient Educ Couns. 2017 May;100(5):812-817. doi: 10.1016/j.pec.2016.11.019. Epub 2016 Nov 22.

PMID:
27923674
16.

Early Stage Bladder Cancer: Do Pathology Reports Tell Us What We Need to Know?

Schroeck FR, Pattison EA, Denhalter DW, Patterson OV, DuVall SL, Seigne JD, Robertson DJ, Sirovich B, Goodney PP.

Urology. 2016 Dec;98:58-63. doi: 10.1016/j.urology.2016.07.040. Epub 2016 Aug 30.

17.

Cognitive and Affective Representations of Active Surveillance as a Treatment Option for Low-Risk Prostate Cancer.

Lyons KD, Li HH, Mader EM, Stewart TM, Morley CP, Formica MK, Perrapato SD, Seigne JD, Hyams ES, Irwin BH, Mosher T, Hegel MT.

Am J Mens Health. 2017 Jan;11(1):63-72. doi: 10.1177/1557988316657041. Epub 2016 Jul 7.

18.

Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline.

Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, Pruthi R, Quale DZ, Ritch CR, Seigne JD, Skinner EC, Smith ND, McKiernan JM.

J Urol. 2016 Oct;196(4):1021-9. doi: 10.1016/j.juro.2016.06.049. Epub 2016 Jun 16. Review.

PMID:
27317986
19.

A single-centre experience with tumour tract seeding associated with needle manipulation of renal cell carcinomas.

Viswanathan A, Ingimarsson JP, Seigne JD, Schned AR.

Can Urol Assoc J. 2015 Nov-Dec;9(11-12):E890-3. doi: 10.5489/cuaj.3278. Epub 2015 Dec 14.

20.

MicroRNA molecular profiling from matched tumor and bio-fluids in bladder cancer.

Armstrong DA, Green BB, Seigne JD, Schned AR, Marsit CJ.

Mol Cancer. 2015 Nov 14;14:194. doi: 10.1186/s12943-015-0466-2.

21.

Robot-assisted partial nephrectomy.

Hyams ES, Seigne JD.

Health Aff (Millwood). 2015 May;34(5):881. doi: 10.1377/hlthaff.2015.0275. No abstract available.

PMID:
25941292
22.

Immunoglobulin G4-related disease in the urinary bladder.

Dropkin BM, Ingimarsson JP, Jones JD, Pettus JR, Seigne JD.

Int J Urol. 2015 Jun;22(6):605-7. doi: 10.1111/iju.12769. Epub 2015 Mar 31.

23.

Expression of tumor suppressive microRNA-34a is associated with a reduced risk of bladder cancer recurrence.

Andrew AS, Marsit CJ, Schned AR, Seigne JD, Kelsey KT, Moore JH, Perreard L, Karagas MR, Sempere LF.

Int J Cancer. 2015 Sep 1;137(5):1158-66. doi: 10.1002/ijc.29413. Epub 2015 Feb 25.

24.

Image-Guided Embolization Coil Placement for Identification of an Endophytic, Isoechoic Renal Mass During Robotic Partial Nephrectomy.

Reeves JJ, Forauer A, Seigne JD, Hyams ES.

J Endourol Case Rep. 2015 Nov 1;1(1):59-61. doi: 10.1089/cren.2015.0022. eCollection 2015.

25.

Cancer-free survival and local tumor control after impendence-based radiofrequency ablation of biopsy-proven renal cell carcinomas with a minimum of 1-year follow-up.

Forauer AR, Dewey BJ, Seigne JD.

Urol Oncol. 2014 Aug;32(6):869-76. doi: 10.1016/j.urolonc.2014.03.016. Epub 2014 Jun 16.

PMID:
24946958
26.

Clinicopathological correlates of Gli1 expression in a population-based cohort of patients with newly diagnosed bladder cancer.

Sverrisson EF, Zens MS, Fei DL, Andrews A, Schned A, Robbins D, Kelsey KT, Li H, DiRenzo J, Karagas MR, Seigne JD.

Urol Oncol. 2014 Jul;32(5):539-45. doi: 10.1016/j.urolonc.2014.03.006. Epub 2014 May 22.

27.

The conundrum of prostatic urethral involvement.

Ingimarsson JP, Seigne JD.

Urol Clin North Am. 2013 May;40(2):249-59. doi: 10.1016/j.ucl.2013.01.010. Epub 2013 Feb 13.

PMID:
23540782
28.

Ureteroscopic biopsy of upper tract urothelial carcinoma using a novel ureteroscopic biopsy forceps.

Wason SE, Seigne JD, Schned AR, Pais VM Jr.

Can J Urol. 2012 Dec;19(6):6560-5.

PMID:
23228292
29.

Regulatory T-cells and associated pathways in metastatic renal cell carcinoma (mRCC) patients undergoing DC-vaccination and cytokine-therapy.

Schwarzer A, Wolf B, Fisher JL, Schwaab T, Olek S, Baron U, Tomlinson CR, Seigne JD, Crosby NA, Gui J, Hampton TH, Fadul CE, Heaney JA, Ernstoff MS.

PLoS One. 2012;7(10):e46600. doi: 10.1371/journal.pone.0046600. Epub 2012 Oct 31.

30.

Presence of benign germ cells in a fine needle aspirate of a spermatocele.

Marotti JD, Seigne JD, Gutmann EJ.

Diagn Cytopathol. 2013 Apr;41(4):342-3. doi: 10.1002/dc.21846. Epub 2011 Nov 1. No abstract available.

PMID:
22045691
31.

Stability of serrated gold coil markers in prostate localization.

Gates LL, Gladstone DJ, Kasibhatla MS, Marshall JF, Seigne JD, Hug E, Hartford AC.

J Appl Clin Med Phys. 2011 Apr 18;12(3):3453.

32.

Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients.

Schwaab T, Schwarzer A, Wolf B, Crocenzi TS, Seigne JD, Crosby NA, Cole BF, Fisher JL, Uhlenhake JC, Mellinger D, Foster C, Szczepiorkowski ZM, Webber SM, Schned AR, Harris RD, Barth RJ Jr, Heaney JA, Noelle RJ, Ernstoff MS.

Clin Cancer Res. 2009 Aug 1;15(15):4986-92. doi: 10.1158/1078-0432.CCR-08-3240. Epub 2009 Jul 21.

33.

A da Vinci robot system can make sense for a mature laparoscopic prostatectomy program.

Steinberg PL, Merguerian PA, Bihrle W 3rd, Heaney JA, Seigne JD.

JSLS. 2008 Jan-Mar;12(1):9-12.

34.

The cost of learning robotic-assisted prostatectomy.

Steinberg PL, Merguerian PA, Bihrle W 3rd, Seigne JD.

Urology. 2008 Nov;72(5):1068-72. doi: 10.1016/j.urology.2007.11.118. Epub 2008 Mar 3.

PMID:
18313121
35.

Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update.

Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigne JD, Skinner EC, Wolf JS Jr, Schellhammer PF.

J Urol. 2007 Dec;178(6):2314-30. Review. No abstract available.

PMID:
17993339
36.

Developing a rational tumor vaccine therapy for renal cell carcinoma: immune yin and yang.

Ernstoff MS, Crocenzi TS, Seigne JD, Crosby NA, Cole BF, Fisher JL, Uhlenhake JC, Mellinger D, Foster C, Farnham CJ, Mackay K, Szczepiorkowski ZM, Webber SM, Schned AR, Harris RD, Barth RJ Jr, Heaney JA, Noelle RJ.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):733s-740s. Review.

37.

Treatment of intermediate-risk prostate cancer with brachytherapy without supplemental pelvic radiotherapy: a review of the H. Lee Moffitt Cancer Center experience.

Torres-Roca JF, Cantor AB, Shukla S, Montejo ME, Friedland J, Seigne JD, Heysek R, Pow-Sang J.

Urol Oncol. 2006 Sep-Oct;24(5):384-90.

PMID:
16962486
38.
39.

A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma.

Rosenberg JE, von der Maase H, Seigne JD, Mardiak J, Vaughn DJ, Moore M, Sahasrabudhe D, Palmer PA, Perez-Ruixo JJ, Small EJ.

Cancer. 2005 May 15;103(10):2035-41.

40.

Surgical management of bladder cancer in 2003.

Wade M, Seigne JD.

Expert Rev Anticancer Ther. 2003 Dec;3(6):781-92. Review.

PMID:
14686700
41.

Devastating complications after brachytherapy in the treatment of prostate adenocarcinoma.

Moreira SG Jr, Seigne JD, Ordorica RC, Marcet J, Pow-Sang JM, Lockhart JL.

BJU Int. 2004 Jan;93(1):31-5.

PMID:
14678363
42.

Continent colonic urinary reservoir (Florida pouch): long-term surgical complications (greater than 11 years).

Webster C, Bukkapatnam R, Seigne JD, Pow-Sang J, Hoffman M, Helal M, Ordorica R, Lockhart JL.

J Urol. 2003 Jan;169(1):174-6.

PMID:
12478129
43.

Prostate adenocarcinoma: cellular and molecular abnormalities.

Mora LB, Buettner R, Ahmad N, Bassel Y, Jove R, Seigne JD.

Cancer Control. 2001 Nov-Dec;8(6):551-61. Review. No abstract available.

PMID:
11807425
44.

Contemporary management of superficial bladder cancer.

Pow-Sang JM, Seigne JD.

Cancer Control. 2000 Jul-Aug;7(4):335-9. Review.

PMID:
10895127
45.

Cytometric analysis of Fas and Bcl-2 expression in normal prostatic epithelium and prostate cancer.

Diaz JI, Pow-Sang JM, Mora LB, Seigne JD, Cantor AB, Dalton WS.

Urol Oncol. 2000 Jul 1;5(4):149-154.

PMID:
10869956
46.

B7-1 gene-modified autologous tumor-cell vaccines for renal-cell carcinoma.

Antonia SJ, Seigne JD.

World J Urol. 2000 Apr;18(2):157-63. Review.

PMID:
10854153
47.

Long-term urodynamic evaluation of a continent urinary reservoir.

Lynch CM, Towsley GA, Pow-Sang JM, Seigne JD, Lockhart JL.

Prim Care Update Ob Gyns. 1998 Jul 1;5(4):200.

PMID:
10838382
48.

Adenocarcinoma in a continent colonic urinary reservoir.

Albertini JJ, Sujka SK, Helal MA, Seigne JD, Lockhart JL.

Urology. 1998 Mar;51(3):499-500.

PMID:
9510363
49.

Gene Therapy of Bladder Cancer.

Seigne JD.

Cancer Control. 1996 Oct;3(5):428-433.

PMID:
10764501
50.

Osteitis pubis as a complication of prostate cryotherapy.

Seigne JD, Pisters LL, von Eschenbach AC.

J Urol. 1996 Jul;156(1):182. No abstract available.

PMID:
8648793

Supplemental Content

Loading ...
Support Center